Genomic analysis in active surveillance: Predicting high-risk disease using tissue biomarkers

Current Opinion in Urology

Volumn 24, Issue 3, 2014, Pages 303-310

  Donovan, Michael J ^a   Cordon Cardo, Carlos ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

active surveillance; biomarkers; liquid biopsy; systems pathology

Indexed keywords

ANDROGEN RECEPTOR; BIOLOGICAL MARKER; HISTONE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PROTEIN P53; TMPRSS2 PROTEIN; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR EZH2; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; TUMOR MARKER;

CANCER INHIBITION; CANCER PROGNOSIS; CANCER RISK; CANCER TISSUE; CIRCULATING TUMOR CELL; DISEASE SURVEILLANCE; EPIGENETICS; GENE EXPRESSION; GENE FUSION; GENE MUTATION; GENE TRANSLOCATION; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOMICS; HIGH RISK POPULATION; HISTONE MODIFICATION; HUMAN; IMMUNE DYSREGULATION; MEDICAL TECHNOLOGY; METASTASIS; MULTIGENE FAMILY; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; TISSUES; TUMOR INVASION; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; MALE; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROSTATIC NEOPLASMS; SYSTEMS BIOLOGY; WATCHFUL WAITING;

GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOMICS; HUMANS; MALE; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; SYSTEMS BIOLOGY; TUMOR MARKERS, BIOLOGICAL; WATCHFUL WAITING;

EID: 84898549199     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0000000000000051     Document Type: Review

References (62)

1. Barbieri CE, Tomlins SA. The prostate cancer genome: perspectives and potential. Urol Oncol 2014; 32:53e15-53e22.
2. Febbo PG. Genomic approaches to outcome prediction in prostate cancer. Cancer 2009; 115:3046-3057.
3. Baca SC, Garraway L. The genomic landscape of prostate cancer. Front Endocrinol 2012; 3:1-9.
4. Haffner MC, Mosbruger T, Esopi D, Fedor H, et al. Tracking the clonal origin of lethal prostate cancer. J Clin Invest 2013; 123:4918-4922.
5. Yatani R, Kusano I, Shiraishi T, et al. Latent prostatic carcinoma: pathological and epidemiological aspects. Jpn J Clin Oncol 1989; 19:319-326.
6. Abate-Shen C, SHen MM, Gelmann E. Integrating differentiation and cancer: the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Differentiation 2008; 76:717-727.
7. Padmanabhan A, Gosc EB, Bieberich CJ. Stabilization of the prostatespecific tumor suppressor NKX3.1 by the oncogenic protein kinase Pim-1 in prostate cancer cells. Hum Mol Genet 2013; 22:408-415.
8. Lei Q, Jiao J, Xin L, et al. NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell 2006; 9:367-378.
9. Lin C, Yang L, Tanasa B, et al. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 2009; 139:1069-1083.
10. Netto GJ, Epstein JI. Theranostic and prognostic biomarkers: genomic applications in urological malignancies. Pathology 2010; 42:384-394.
11. Ding Z, Wu C-J, Chu GC, et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011; 470:269-273.
12. Qin J, San-Pin Wu. Creighton C, Dai F, et al. COUP-TFII inhibits TGF-binduced growth barrier to promote prostate tumorigenesis. Nature 2013; 493:236-240.
13. Jeronimo C, Bastian P, Bjartell A, Carbone G, et al. Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol 2011; 60:753-766.
14. Bhavsar T, McCue P, Birbe R. Molecular diagnosis of prostate cancer: are we up to age? Semin Oncol 2013; 40:259-275.
15. Chen H, Toyooka S, Gazdar AF, et al. Epigenetic regulation of a novel tumor suppressor gene (DAB2IP) in prostate cancer cell lines. J Biol Chem 2003; 278:3121-3130.
16. Min J, Zaslavsky A, Fedele G, et al. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med 2010; 16:286-294.
17. Wu K, Xie D, Zou Y, Zhang T, et al. The mechanism of DAB2IP in chemoresistance of prostate cancer cells. Clin Cancer Res 2013; 19:4740- 4749.
18. Shariat SF, Karakiewicz PI, Suardi N, et al. Comparison of nomograms and other methods for predicting outcomes in prostate cancer: a critical analysis of the literature. Clin Cancer Res 2008; 14:4400-4407.
19. Moul JW, Mouraviev V, Sun L, et al. Prostate cancer: the new landscape. Curr Opin Urol 2009; 19:154-160.
20. Cooperberg MR, Konety BR. Management of localized prostate cancer in men over 65 years. Curr Opin Urol 2009; 19:309-314.
21. Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360:1310- 1319.
22. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360:1320- 1328.
23. Amin A-O, Kote-Jarai Z, Schumacher FR, Wiklund F. A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and nonaggressive disease. Expert Opin Ther Targets 2012; 16:121-130.
24. Shui I, Lindstrom S, Kibel A, Berndt S, et al. Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Eur Urol 2014. [Epub 7ahead of print].in press, http://dx.doi.org/10.1016/j.eururo.2013.12.058.
25. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310:644- 648.
26. Perner S, Mosquera J-M, Demichelis F, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 2007; 31:882-888.
27. Mehra R, Tomlins SA, Shen R, et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007; 20:538-544.
28. Carver BS, Tran J, Gopalan A, Chen Z, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 2009; 41:619-624.
29. Carver BS, Tran J, Chen Z, Carracedo-Perez A, et al. ETS rearrangements and prostate cancer initiation. Nature 2009; 457:E1.
30. Reid AH, Attard G, Ambroisine L, Fisher G, et al. Molecular characterization of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 2010; 102:678-684.
31. Han B, Mehra R, Lonigro RJ, Wang L, et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol 2009; 22:1083-1093.
32. Attard G, Clark J, Ambroisine L, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2009; 27:253-263.
33. Clark JP, Cooper CS. ETS gene fusions in prostate cancer. Nat Rev Urol 2009; 6:429-439.
34. Gopalan A, Leversha MA, Satagopan JM, Zhou Q, et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 2009; 69:1400-1406.
35. Pettersson A, Graff RE, Bauer SR, et al. The TMPRSS2:ERG rearrangement, ERG expression and prostate cancer outcomes: a cohort study and metaanalysis. Cancer Epidemiol Biomarkers Prev 2012; 21:1497-1509.
36. Lin DW, Newcomb LF, Brown EC, et al. Urinary TMPRSS2:ERGand PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res 2013; 19:2442- 2450.
37. Hessles D, Smit FP, Verhaegh GW, Witjes JA, et al. Detection of TMPRSS2- ERG transcripts and prostate cancer antigen 3 in urinary sediments may improve the diagnosis of prostate cancer. Clin Cancer Res 2007; 13:5103- 5108.
38. Baena E, Shao Z, Linn DE, Glass K. ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes Dev 2013; 27:683-698.
39. Brenner JC, Ateeq B, Li Y, Yocum A, et al. Mechanistic rationale for inhibition of Poly(ADP-Ribose) polymerase in ETS gene fusion-positive cancer. Cancer Cell 2012; 19:664-678.
40. Penney KL, Pyne S, Schumacher FR, et al. Genome-wide association study of prostate cancer mortality. Cancer Epidemiol Biomarkers Prev 2010; 19:2869-2876.
41. Ishkanian AS, Zafarana G, Thomas J, et al. Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer. Acta Oncol 2010; 49:888-894.
42. Berger MF, Lawrence MS, Demichelis F, et al. The genomic complexity of primary human prostate cancer. Nature 2011; 470:214-220.
43. Bartholomeusz C, Gonzalez-Angulo AM. Targeting the PI3K signaling pathway in cancer therapy. Proc Natl Acad Sci U S A 2011; 108:21276- 21281.
44. Taylor BS, Schulta N, Hieronymus H, et al. Integrative genomic proofing of human prostate cancer. Cancer Cell 2010; 18:11-22.
45. Markert EK, Mizuno H, Vazques A, Levine AJ. Molecular classification of prostate cancer using curated expression signatures. Cancer Cell 2012; 22:373-388.
46. Saidi O, Cordon-Cardo C, Costa J. Technology insight: will systems pathology replace the pathologist? Nat Clin Pract Urol 2007; 4:39-45.
47. Costa J. Is clinical systems pathology the future of pathology? Arch Pathol Lab Med 2008; 132:774-776.
48. Cordon-Cardo C, Kotsianti A, Verbel D, et al. Improved prediction of prostate cancer recurrence through systems pathology. J Clin Invest 2007; 117:1876- 1883.
49. Donovan MJ, Costa J, Cordon-Cardo C. Systems pathology: a paradigm shift in the practice of diagnostic and predictive pathology. Cancer 2009; 115:3078-3084.
50. Donovan MJ, Khan FH, Fernandez G, et al. Personalized prediction of tumor response and cancer progression on prostate needle biopsy. J Urol 2009; 1:125-132.
51. Donovan MJ, Hamann S, Clayton M, et al. Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy. J Clin Oncol 2008; 26:3923-3929.
52. Donovan MJ, Khan FH, Powell D, et al. Previously developed systems-based model (Prostate PxBE;) identifies favorable-risk prostate cancer for men enrolled in active surveillance program. J Urol 2011; 185:e517-e518.
53. Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch and hedgehog-dependent tumor-initiating cells. Cancer Cell 2012; 22:373- 388.
54. Anand PK. Exosomal membrane molecules are potent immune response modulators. Commun Integr Biol 2010; 3:405-408.
55. Chen C, Skog J, Hsu CH, et al. Microfluidic isolation and transcriptome analysis of serum microvesicles. Lab Chip 2010; 10:505-511.
56. Prenser JR, Iyer MK, Sahu A, et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF comples. Nat Genet 2013; 45:1392-1398.
57. Prensner JR, Chen W, Iyer MK, et al. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res 2014; in press.
58. Peinado H, Aleckovic M, Lavotshkin S, et al. Melanoma exosomes educate bone marrow progenitor cells toward a prometastatic phenotype through MET. Nat Med 2012; 18:883-891.
59. Nilsson J, Skog J, Nordstrand A, et al. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br J Cancer 2009; 100:1603-1607.
60. De Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14:6302-6309.
61. Diamond E, Lee GY, Akhtar NH, et al. Isolation and characterization of circulating tumor cells in prostate cancer. Front Oncol 2012; 2: 131.
62. Hu B, Rochefort H, Goldkorn A. Circulating tumor cells in prostate cancer. Cancer 2013; 5:1676-1690.